Top executives from three high-flying biotechs, all have gone public on Nasdaq and Hong Kong Stock Exchange, offering lessons learned and looking forward to what’s ahead for Chinese biotech.

CMS final rule for hospital payment in 2021 includes enhanced payment for six novel antibiotics – including one that is not yet approved by FDA. New policies to encourage antibiotic innovation are clearly having an impact in the context of Medicare payments.

Pharma-backed investment fund to combat antimicrobial resistance aims to find Phase II-ready programs, but can’t generate a constant flow of innovation without better ‘pull’ incentives, industry says.

The industry-backed investment fund to combat antimicrobial resistance hopes to be operational by end of year and begin assessing programs to invest in during the first quarter of 2021.